Dr. Nambiar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8300 Floyd Curl Drive
4A
San Antonio, TX 78229Phone+1 210-450-9800Fax+1 210-450-4935
Summary
- Anoop Nambiar, MD, is a pulmonologist based in San Antonio, TX, with subspecialties in interstitial lung diseases, including autoimmune-related ILDs, hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. He completed his residency and fellowship at the University of Michigan and holds an MS in Clinical Investigation from The University of Texas Health Science Center at San Antonio. Dr. Nambiar has been serving as a staff pulmonologist at Audie L. Murphy VA Hospital and a pulmonologist at UT Health San Antonio since 2010. In addition to patient care and teaching, he has robust research experience serving as principal investigator for multiple clinical studies ranging from investigator-initiated and industry-sponsored, phase 1 to phase 3 randomized controlled trials. He has published multiple studies, including those cited extensively, and participates in several clinical trials related to idiopathic pulmonary fibrosis. He is founding director of the UT Health San Antonio's Center for ILD, a Pulmonary Fibrosis Foundation Care Center, 1 of 81 in the U.S., 1 of 5 in Texas, and the only one in South Texas.
Education & Training
- The University of Texas Health Science Center at San AntonioMS, Clinical Investigation, 2014 - 2016
- University of MichiganFellowship, Pulmonary Disease and Critical Care Medicine, 2006 - 2009
- University of MichiganResidency, Internal Medicine, 2003 - 2006
- Rutgers New Jersey Medical SchoolClass of 2003
Certifications & Licensure
- TX State Medical License 2010 - 2026
- MI State Medical License 2003 - 2010
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2008 Aug 01
- Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2011 Jun 01
- A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Oct 13
- Join now to see all
Publications & Presentations
PubMed
- Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis.Rebecca Keith, Anoop M Nambiar
Therapeutic Advances in Respiratory Disease. 2025-01-02 - A Low Forced Vital Capacity (FVC)/Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Ratio Increases Clinical Suspicion for Fibrotic Hypersensitivity Pneumoniti...Tannam S Vongvivitpatana, Anoop M Nambiar
Cureus. 2024-11-01 - Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review.Gabriele Bongiovanni, Antonio Tonutti, Anna Stainer, Mattia Nigro, Dean L Kellogg 3rd
BMJ Open Respiratory Research. 2024-03-13
Press Mentions
- Admilparant Affects Biomarkers in Pulmonary FibrosisSeptember 16th, 2024
- Experts Debate While West Texas Doctor Stands Ground on Inhaled Steroid for COVID-19September 7th, 2020
- Can We Halt Cellular Aging? New Drug Combo Shows PromiseFebruary 20th, 2019
- Join now to see all
Professional Memberships
- Fellow
- Member
- European Respiratory SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: